Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg Manufacturer

Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg Manufacturer in India – Healthy Life Pharma Pvt. Ltd.

Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg Manufacturer product packaging

Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg | Manufacturer

Product image for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg Manufacturer; contract manufacturing, oem & quality control.

Product Information

Generic NameLamivudine and Zidovudine
ManufacturerHealthy Life Pharma Pvt. Ltd.
HSN Code30049099
PharmacopoeiaIP
Product TypeTablet
CategoryAntiviral drugs
SubcategoryAntiviral drugs
Active IngredientLamivudine and Zidovudine
Strength300 mg + 150 mg
Dosage FormTablet
Pack Size10 x 10 Tablets / Box (Alu-Alu / Blister)
Route of AdministrationOral
Prescription RequiredYes
Therapeutic CategoryAntiviral drugs

Medicine Details & Safety

Short DescriptionHealthy Life Pharma invites contract and third-party manufacturing enquiries for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements.
Approved Uses / Indications1. Treatment of initial and recurrent mucocutaneous and genital Herpes Simplex (HSV-1, HSV-2) outbreaks. 2. Management of Herpes Zoster (shingles), Varicella (chickenpox), and suppression of recurrent viral infections.
Full Description

Healthy Life Pharma invites contract and third-party manufacturing enquiries for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements.

Product technical specifications

Generic nameLamivudine and Zidovudine
CompositionLamivudine and Zidovudine
Strength300 mg + 150 mg
CategoryAntiviral drugs
PharmacopoeiaIP
Dosage formTablet

Product technical specifications

Generic nameAcarbose
CompositionAcarbose
Strength25 mg
CategoryAntidiabetic Drugs
PharmacopoeiaUSP / IP
Dosage formTablet

Manufacturing capabilities and infrastructure

For Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg, assess the approved formulation process, equipment suitability, batch scale and in-process controls for the Tablet presentation. Confirm environmental requirements and validated process before production.

Quality control and assurance

Request the approved finished-product specification for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg, including applicable identity, assay, uniformity and performance tests for the Tablet presentation. Confirm analytical methods, acceptance criteria and batch release documentation, including COA availability.

Primary and secondary packaging

The catalogue pack for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg is 10 x 10 Tablets / Box (Alu-Alu / Blister). Confirm primary packaging compatibility, stability evidence, artwork, batch coding and leaflet requirements against the approved specification.

Contract manufacturing and private label

Submit the target market, strength, pharmacopoeial specification, forecast volume and brand artwork. Agree feasibility, batch size, quality agreement, production schedule and release criteria before execution.
Dosage InstructionsAdminister orally with plenty of fluids. Initiate therapy at the earliest symptom of viral outbreak or prodromal tingling. Adhere strictly to the dosing schedule for the full recommended duration.
Side EffectsCommon: Nausea, headache, diarrhea, abdominal pain, fatigue, mild pruritus. Uncommon: Dizziness, fever, skin rash, arthralgia, transient elevation in bilirubin. Rare: Reversible neurological disturbances, renal tubular crystallization in dehydration.
Warnings and PrecautionsAdequate Hydration: Maintain abundant fluid intake throughout therapy to avoid crystalluria and renal tubular damage. Renal Dose Adjustment: Dose reduction is mandatory in renal impairment based on creatinine clearance. Early Initiation: Therapeutic efficacy is maximal when started within 24 to 72 hours of outbreak.
Contraindications1. Known hypersensitivity to Lamivudine and Zidovudine or chemically related nucleoside antiviral analogues.
2. Severe uncorrected dehydration.
3. Severe acute renal failure unless coordinated with hemodialysis.
Drug Interactions1. Probenecid & Cimetidine: Compete for active renal tubular secretion, increasing antiviral AUC and elimination half-life.
2. Nephrotoxic Medications (Aminoglycosides, Cyclosporine, Amphotericin): Synergistic potential for renal injury.
3. Mycophenolate Mofetil: Co-administration elevates plasma concentrations of both compounds.

Frequently Asked Questions

QuestionAnswer
Can I request third-party manufacturing for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg?Submit your brand, quantity and packaging requirements for manufacturing feasibility review.
Which pharmacopoeial standard applies for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg?The source specification is IP; confirm the required standard before contracting.
What quality tests are applicable for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg?Request the approved finished-product specification and batch testing plan.
Can packaging be customized for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg?Submit artwork and pack requirements for technical and regulatory review.
How do I request a manufacturing quotation for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg?Provide forecast volume, target market, strength and packaging requirements.

Product Hashtags

#Lamivudine#Manufacturer#PharmaB2B

Related Products

Latest Posts